摘要
目的探讨抗雌激素治疗中晚期原发性肝癌的价值。方法采用单克隆抗体、免疫组化技术检测癌组织雌激素受体（ＥＲ）的表达。５１例随机分成治疗组（２６例）和对照组（２５例）。对照组单用吗特灵和免疫核糖核酸治疗，治疗组用吗特灵、免疫核糖核酸加他莫昔芬（ＴＡＭ）治疗。结果ＥＲ（＋）治疗组与ＥＲ（－）治疗组和ＥＲ（＋）对照组、ＥＲ（－）对照组相比，血清ＡＦＰ水平下降５０％者显著增加（Ｐ＜０．０５），病灶缩小５０％者显著增加（Ｐ＜０．００１）。在ＥＲ（＋）对照组、ＥＲ（－）对照组和ＥＲ（－）治疗组之间，血清ＡＦＰ下降５０％出现率、病灶缩小５０％出现率和部分缓解率差异均无显著性。各组无一例完全缓解。结论原发性肝癌ＥＲ阳性者，采用他莫昔芬治疗可能是一种比较有效的、可供选择的治疗方案。
Objective To study the usefulness of anti estrogen therapy for moderately and advanced hepatocellular carcinoma (HCC).Methods Estrogen receptors (ER) were examined in 51 cases of HCC by immunohistochemical staining of needle aspiration biopsy HCC specimens. The cases studied were randomly divided into two groups: the control group (N=25) and the anti estrogen treated group (N=26). Patients in the control group were given matelin and immune RNA while those in the anti estrogen treated group were given Tamoxifen in addition. A 50% reduction of serum AFP level and a 50% decrease in tumor size were considered therapeutically effective.Results In the control group, the response rate as judged by AFP level (RR AFP) and by tumor size (RR TS) in the ER + patients was 42.9% (3 of 7 cases) and 14.3% (1 of 7 cases), respectively, while the 2 RRs in the ER - patients were lower but the difference was statistically insignificant. In contrast, in the Tamoxifen treated group, RR AFP was 83.3% (5 of 6 cases) and RR TS was 50.0% (3 of 6 cases). The difference in RRs of ER + patients in the 2 groups was statistically significant. No complete remission was observed.Conclusion Endocrinotherapy may be of value in the treatment of ER + HCC.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
1997年第6期451-453,共3页
Chinese Journal of Oncology
关键词
肝肿瘤
免疫组织化学
激素疗法
他莫昔芬
Liver neoplasms/therapy Receptors, estrogen Immunohistochemistry
